CBR

EN

Scientific Achievements

  • Home
  • Scientific Achievements

Scientific Achievements

Among other things the CCRD research team performs tests of new medical devices, drugs and treatment methods of cardiovascular diseases

Our research work includes evaluation of local administration of drugs in arteriosclerosis and in prevention of restenosis after angioplasty procedures, investigation for preventing myocardial reperfusion injury after angioplasty, as well as methods for myocardial regeneration and vessel regeneration after cardiac infarction

We develop and test novel methods of valve reparation and percutaneous heart valve implantation, new intravascular stents including biodegradable stents and novel techniques of interventional treatment of hypertension. We also try to limit central nervous system damages caused by ischemia due to application of stem cells.

Over the last several years of CCRD AHP operation, we managed to achieve great success. Projects conducted in CCRD allowed for introduction to the clinical practise, among other things:

first Polish coronary stent made of stainless steel 316L “Chopin”
coronary stent made of cobalt-chromium alloy “KOS”
first Polish anti-proliferative biodegradable polymer-coated paclitaxel-eluting stent (Luc-Chopin2)
“Shellak” coating used on stent and balloon surfaces
coronary stent “Alex” eluting sirolimus
antiproliferative drug-coated balloons

In 2006,  CCRD AHP scientists were awarded by the “Working Group of Interventional Cardiology” for a study “Biodegradable polymer coated, paclitaxel eluting stents in the porcine coronary arteries”. In April 2014, during an International Conference on Interventional Cardiology in Seoul, our General Director was awarded the prize “TCTAP Best Presenter” for his presentation of an innovative program of hybrid procedures implemented by CCRD AHP.

View Our Publications

  • Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.
    Buszman PP, Michalak MJ, Pruski M, Fernandez C, Jelonek M, Janas A, Savard C, Gwiazdowska-Nowotka B, Żurakowski A, Wojakowski W, Buszman PE, Milewski K.
    Cardiol J. 2016;23(6):657-666.

  • A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly-l-Lactide Biodegradation Kinetics From Stent-Polymer Matrices: An Experimental Study Utilizing Porcine Model of In-Stent Restenosis.
    Orlik B, Buszman PP, Krauze A, Gąsior P, Desperak P, Pająk J, Kasperczyk J, Janas A, Jelonek M, Handzlik-Orlik G, Buszman PE, Milewski K.
    J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):93-9.

  • Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for De Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial.
    Żurakowski A, Buszman PP, Milewski KP, Janas A, Gorycki B, Kondys M, Gąsior P, Michalak M, Boxberger M, Peppas A, Granada JF, Buszman PE.
    J Interv Cardiol. 2015 Aug;28(4):348-57.

  • Dose-dependent vascular response following delivery of sirolimus via fast releasing, biodegradable polymer stent matrix: an experimental study in the porcine coronary model of restenosis.
    Buszman PP, Orlik B, Pająk J, Jelonek M, Krauze A, Janas A, Legutko J, Wojakowski W, Buszman PE, Milewski K.
    Kardiol Pol. 2015;73(10):916-23.

  • Eptifibatide infusion versus placebo in high risk patients with non-st segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.
    Wilczynski M, Wybraniec MT, Milewski K, Sanak M, Wita K, Buldak L, Kondys M, Buszman P, Bochenek A.
    J Cardiovasc Surg (Torino). 2014 Nov 14.

Do góry